IRIS
BALLABENI, Vigilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.869
AS - Asia 8.079
EU - Europa 6.910
SA - Sud America 1.087
AF - Africa 430
Continente sconosciuto - Info sul continente non disponibili 162
OC - Oceania 7
Totale 30.544
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.526
SG - Singapore 2.765
CN - Cina 2.448
VN - Vietnam 1.268
FI - Finlandia 1.264
SE - Svezia 1.092
IE - Irlanda 940
IT - Italia 855
BR - Brasile 852
DE - Germania 783
UA - Ucraina 708
HK - Hong Kong 563
FR - Francia 289
ZA - Sudafrica 267
GB - Regno Unito 259
TR - Turchia 245
BD - Bangladesh 244
NL - Olanda 233
CA - Canada 204
RU - Federazione Russa 122
IN - India 117
AR - Argentina 87
BE - Belgio 69
MX - Messico 62
CI - Costa d'Avorio 57
AT - Austria 56
ES - Italia 55
IQ - Iraq 51
ID - Indonesia 46
RO - Romania 46
JP - Giappone 45
PH - Filippine 41
EC - Ecuador 39
KR - Corea 37
PK - Pakistan 36
TH - Thailandia 36
CZ - Repubblica Ceca 35
PL - Polonia 31
CM - Camerun 25
CO - Colombia 25
EU - Europa 24
VE - Venezuela 22
MA - Marocco 20
PY - Paraguay 19
CR - Costa Rica 16
TW - Taiwan 16
UZ - Uzbekistan 16
CL - Cile 14
JM - Giamaica 14
MY - Malesia 14
EG - Egitto 13
LT - Lituania 13
PA - Panama 13
AZ - Azerbaigian 12
PE - Perù 11
TN - Tunisia 11
DO - Repubblica Dominicana 8
ET - Etiopia 8
LB - Libano 8
NP - Nepal 8
UY - Uruguay 8
BO - Bolivia 7
KZ - Kazakistan 7
PT - Portogallo 7
SA - Arabia Saudita 7
SI - Slovenia 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
BG - Bulgaria 6
DZ - Algeria 6
HN - Honduras 6
IR - Iran 6
JO - Giordania 6
KE - Kenya 6
NI - Nicaragua 6
AL - Albania 5
EE - Estonia 5
SY - Repubblica araba siriana 5
TT - Trinidad e Tobago 5
DK - Danimarca 4
HU - Ungheria 4
IL - Israele 4
OM - Oman 4
SC - Seychelles 4
SN - Senegal 4
BY - Bielorussia 3
HR - Croazia 3
MD - Moldavia 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
BB - Barbados 2
BN - Brunei Darussalam 2
CH - Svizzera 2
CY - Cipro 2
GA - Gabon 2
GE - Georgia 2
GY - Guiana 2
KG - Kirghizistan 2
KH - Cambogia 2
Totale 30.380
Salva come PNG Salva come JPEG
Città #
Dallas 4.215
Singapore 1.457
Ashburn 1.028
Dublin 939
Chandler 911
San Jose 864
Jacksonville 746
Santa Clara 666
Beijing 576
Hong Kong 536
Dearborn 450
Ann Arbor 448
Ho Chi Minh City 409
Boardman 327
Council Bluffs 303
Hanoi 270
Johannesburg 255
Nanjing 246
New York 240
Los Angeles 210
Izmir 197
Parma 194
Munich 183
Princeton 179
Shanghai 172
Lauterbourg 166
San Mateo 132
Wilmington 127
Hefei 124
Toronto 118
Helsinki 105
Buffalo 89
Bremen 88
Hebei 83
Kunming 78
Jinan 75
Nanchang 75
Shenyang 75
São Paulo 71
Moscow 70
Brussels 66
Grafing 64
Frankfurt am Main 60
Abidjan 57
Chicago 55
Woodbridge 55
Guangzhou 54
Haiphong 52
Tianjin 52
Turku 51
Milan 49
Vienna 48
Des Moines 45
Changsha 44
Da Nang 44
Columbus 43
London 39
Tokyo 38
Seattle 35
Brooklyn 32
Montreal 32
Rio de Janeiro 30
Bologna 28
Fremont 27
Jiaxing 27
Phoenix 27
Warsaw 25
Auburn Hills 24
Atlanta 23
Norwalk 23
The Dalles 23
Hangzhou 22
Houston 22
Pune 22
Marseille 21
Denver 20
Zhengzhou 20
Amsterdam 19
West Jordan 19
Belo Horizonte 18
Biên Hòa 18
Jakarta 18
Orem 18
Stockholm 18
Bengaluru 17
Boston 17
Brno 17
Lubbock 17
Ninh Bình 17
Redondo Beach 17
Rome 17
Baghdad 16
Bangkok 16
Brasília 16
Chennai 16
Manchester 16
Mexico City 16
San Francisco 16
Curitiba 15
Hải Dương 15
Totale 19.285
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.720
1,5-Benzodiazepines Part XIII. Substututed 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines and 4H-imidazo-[1,2-a][ 1,5]benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity 1.693
1,5-Benzodiazepin tricyclic derivatives as analgersic, anti-inflammatory and /or antipyretic agents with very low acute gastrolesivity and toxicity 1.625
1,8-Naphthyridines V. Novel N-substituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity 260
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 257
2-Aminobenzimidazoles as new potent H3-antagonists 230
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 229
Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador 227
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 220
A promising imidazole-free histamine H3 receptor antagonist with good brain penetration and anticholinesterase activity. 220
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 213
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 207
Antinociceptive and gastroprotective effects of inhaled and orally administered Lavandula hybrida Reverchon “Grosso” essential oil 205
Analgesic properties of benzisothiazole/ benzimidazole derivatives with acidic groups 203
Protective Effects of a Protease Inhibitor (Gabexate Mesilate) on Intestinal Ischemia/Reperfusion Injury in Rats 200
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 199
Aminobenzimidazoles as new potent H3-antagonists 199
1,8-Naphthyridines VIII. Novel 5-aminoimidazo[1,2-a] [1,8]naphthyridine-6-carboxamide and 5-amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. 199
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 198
1,8-Naphthyridines VII. New substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity. 196
2,4-Substituted benzopyrano[4,3-d]pyrimidines and benzopyrano[4,3-d]pyrimidin-5-ones: synthesis and antiplatelet activity 194
2-Amino-1,2-benzisothiazolin-3-one derivatives as powerful antiplatelet agents 190
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 188
The Role of HB-Donor Groups in the Heterocyclic Polar Fragment of H3-Antagonists. I. Synthesis and Biological Assays 185
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 183
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 183
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 181
Histamine H4 receptor antagonism and mesenteric ischemia/reperfusion injury in mice 181
Caratterizzazione farmacologica in vitro di nuovi agonisti muscarinici analoghi dell'Oxotremorina 181
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 180
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 180
Gastrointestinal symptoms and local oxidative stress in a model of Parkinson's Disease in rats 179
Daily assumption of fermented milk containing Bifidobacterium breve 246 B® promotes prophylactic effects against intestinal inflammation in mice 177
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 175
Distinct Roles of α4β2 and α7 Nicotinic Receptors in the Modulation of Inflammatory Responses in TNBS-Induced Colitis 173
Adaptive changes in rat ileum motility induced by mild mesenteric ischemia/reperfusion injury: role of endogenous mediators and reperfusion time 172
Accommodation and peristalsis are functional responses to obstruction in rat hypertrophic ileum 171
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 170
Analgesici-antipiretici benzopirano pirimidinici non acidici attivi per via orale privi di gastrolesività 169
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 168
Dual-Acting Drugs: an in vitro Study of Nonimidazole Histamine H(3) Receptor Antagonists Combining Anticholinesterase Activity 168
2-Amino-1,2-benzisothiazolin-3-one Derivatives: Synthesis and Assessment of their Antiplatelet/Spasmolytic Effects 168
5-HT1A receptors as target to protect the intestine in an experimental model of colitis 167
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 166
Anomalous responses to histamine stimulation of guinea-pig oesophageal muscularis mucosae. 164
Discovery of small-molecule targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases 163
Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity 163
Intestinal chronic obstruction affects motor responsiveness of rat hypertrophic longitudinal and circular muscles 163
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 163
5-Alkoxy-2-hydrazino and 5-methoxy-2-amino-5H[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological activity 161
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 161
Motor responses of rat hypertrophic intestine following chronic obstruction 160
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 160
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 159
Intestinal Hypoxia and reperfusion: role for Eph-ephrin system 157
Anomalous responses to histamine stimulation of guinea-pig oesophageal muscularis mucosae 156
Role of 5-HT in intestinal ischemia-reperfusion: suppression of inflammatory events by 5-HT1A blockade in mice 155
Nuovi potenti agonisti muscarinici oxotremorina-M simili a struttura acetilenica: studio funzionale in vitro 155
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 154
Alterations of intestinal motor responsiveness in a model of mild mesenteric ischemia/reperfusion in rats 154
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 153
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "Grosso" 153
Assessment of intestinal motor responsiveness in an ischemia/reperfusion model in rats 153
Regional differences in motor responsiveness to antimuscarinic drugs in rabbit isolated small and large intestine 152
Brain Pharmacokinetics of Non-Imidazole Biphenyl H3 Receptor Antagonists: a Liquid Chromatography/Electrospray-Mass Spectrometry and ex vivo Binding Study in Rats 152
Influence of Nitric Oxide system in mesenteric ischemia-reperfusion induced injury in mice 152
Influence of adenosine in the systemic and local injury caused by mesenteric ischemia-reperfusion in mice 152
Assessment of intestinal motor responsiveness in an ischemia/reperfusion model in rats 149
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 148
CNS access of selected H3-antagonists: ex vivo binding study in rats 147
Functional Studies of New Imidazole H3-Antagonists on Guinea-Pig Isolated Preparations 146
Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity 145
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 145
2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation 144
Synthesis and biological evaluation of new non-imidazole H(3)-receptor antagonists of the 2-aminobenzimidazole series 144
Preliminary study of calcium balance and bone mineralization improvement by a new calcium supplement in growing rats 144
In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity. 143
The selective inhibition of inducible nitric oxide synthase prevents intestinal ischemia-reperfusion injury in mice 142
Different role of the Histamine H3 Receptor in Vagal-, Betanechol-, Pentagastrin-induced Gastric Acid Secretion in Anaesthetized Rats 140
Discovery of histamine H3 receptor antagonistic property of simple imidazole-free derivatives: preliminary pharmacological investigation. 140
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 139
Radiological analysis of gastrointestinal dysmotility associated with central dopaminergic impairment in an animal model of parkinson's disease (PD) 137
Disruption of Eph-ephrin B signaling pathways mitigates inflammation in a murine model of Crohn’s disease 137
RESPONSIVENESS OF LONGITUDINAL AND CIRCULAR MUSCLE TO RELAXING MEDIATORS IS DIFFERENTIALLY AFFECTED IN RAT HYPERTROPHIED ILEUM 136
Proteinase-Activated Receptor 2 agonist prevents mesenteric ischemia/reperfusion injury in rats: partila involvement of Substance P (SP) and Calcitonin-Gene Related Peptide (CGRP) 135
R-a-methylhistamine-induced inhibition of gastric acid secretion in pylorus-ligated rats via central histamine H3 receptors 135
Histamine H3-antagonists: the basicity of the polar group in quantitative structure-activity and structure-property relationship 134
Protection by the EPH-EPHRIN System Against Mesenteric Ischemia-Reperfusion Injury 134
Evidence for the involvement of 5-HT(2A) receptors in mild mesenteric ischemia/reperfusion dysfunctions in mice 133
Role of Glutamate- N-methyl-D-Aspartate (NMDA) Receptors in Neuronal Plasticity and Gastrointestinal Transit Delay Induced by Ischemia/Reperfusion in Rats 133
Synthesis and pharmacological screening of novel non-acidic gastric-sparing antiinflammatory/antiplatelet agents:5-alkyl/cycloalkylamino substituted 2-amino-5H-[1]benzopyrano[4,3-d]pyrimidines 133
Pharmacological screening of novel antiplatelet agents with analgesic activity 133
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 131
Mesenteric ischemia-reperfusion: an overview of preclinical drug strategies 130
Effects of CCL20/CCR6 modulators in a T cell adoptive transfer model of colitis 129
Synthesis and Biological Evaluation of N-Pyrazolyl-N'-alkyl/benzyl/phenylureas: a New Class of Potent Inhibitors of Interleukin 8-Induced Neutrophil Chemotaxis 129
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 129
Screening di nuovi agenti antiinfiammatori/antiaggreganti non-acidici: sviluppo di 2-amino-5H-[1]benzopirano[4,3-d]pirimidine 5-alchil/cicloalchilamino sostituite prive di attivita' gastrolesiva 129
Involvement of 5-HT2A receptors in motor and inflammatory disorders induced by mesenteric ischemia reperfusion in mice 128
Functional comparison between nuvenzepine and pirenzepine on different guinea pig isolated smooth muscle preparations 128
Totale 21.093
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.639
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.639
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.010 0 30 25 111 62 85 121 136 41 65 77 257
2022/20233.734 445 375 229 259 385 411 71 213 1.124 40 121 61
2023/20241.332 81 106 45 52 106 348 115 67 49 74 95 194
2024/20254.199 122 227 295 225 367 499 144 182 468 412 362 896
2025/202613.064 880 1.680 3.915 958 1.250 546 977 302 1.294 690 339 233
2026/2027666 251 415 0 0 0 0 0 0 0 0 0 0
Totale 30.544